Fish Collagen Peptides Market Size & Share 2026-2035

Fish Collagen Peptides Market Size

The global fish collagen peptides market was valued at USD 715 million in 2024 and reached USD 850 million in 2025. It is projected to reach USD 1.8 billion by 2035, expanding at an approximately 7.5% CAGR during 2026 to 2035.

Fish collagen peptides are hydrolyzed proteins recovered principally from skins, bones, scales, and fins generated by seafood processing. Their commercial relevance rests on converting a variable, low-value byproduct stream into standardized ingredients for supplements, food, cosmetics, and specialized health applications.

Marine raw materials offer an identifiable positioning advantage where brands require non-bovine and non-porcine inputs. Fish-processing byproducts can account for a substantial portion of harvested fish mass, while skin is a particularly attractive feedstock because it is collagen-rich and does not require the mineral-removal step necessary for scales and bones ^{[1]frontiersin.org - https://www.frontiersin.org/journals/aquaculture/articles/10.3389/faquc.2026.1755817/full}. That feedstock advantage is not automatically a cost advantage: species, season, cold-chain handling, contaminant control, enzyme selection, and membrane performance determine whether a processor can produce a consistent peptide specification.

The market is moving beyond commodity hydrolysates toward ingredients defined by source traceability, molecular-weight distribution, sensory performance, and application-specific evidence. Published crossover research has found that hydroxyproline-containing peptides from fish-skin collagen hydrolysates are absorbed following oral intake, supporting the commercial emphasis on hydrolysis control and peptide characterization rather than collagen origin alone ^{[2]frontiersin.org - https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2024.1416643/full}. For suppliers, the operational challenge is to make those attributes reproducible at scale; for formulators, it is to avoid treating clinically studied peptide compositions as interchangeable with generic collagen powder.

Regulatory conditions reinforce this distinction. The European Commission maintains specific rules for imports of collagen and gelatin for human consumption, including establishment-listing requirements and origin-related controls. In the United States, FDA maintains export-listing requirements for establishments seeking to supply collagen and gelatin to EU and UK markets. These systems make documented sourcing, sanitary controls, and traceable processing commercially material, especially for producers pursuing cross-border premium applications.

The market's principal boundary is therefore quality assurance, not feedstock availability. As branded customers seek documented sustainability credentials and composition-specific substantiation, certification and clinical evidence become qualification tools rather than marketing add-ons. This favors established ingredient platforms and capable regional producers, while leaving lower-specification capacity concentrated in price-sensitive outlets.

The market assessment covers 2022 to 2024 historical developments, uses 2025 as the base year, and provides forecasts for 2026 to 2035. It addresses North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Country coverage includes the United States and Canada; Germany, the UK, France, Spain, and Italy; China, India, Japan, Australia, and South Korea; Brazil and Mexico; and Saudi Arabia, South Africa, and the UAE.

The segmentation covers raw material source, molecular weight, application, and distribution channel. Raw material source includes skin, bones, scales, and fins. Molecular-weight categories include ultra-low, low, medium, high, and other specialty fractions. Applications include food and beverage, nutraceuticals, cosmetics, pharmaceuticals, and animal nutrition. Distribution channels include online retail/e-commerce, pharmacies and drug stores, supermarkets/hypermarkets, specialty stores, and direct-to-consumer sales.

Key Drivers

Clean-label positioning and traceable circular sourcing

Fish collagen peptides are well placed in formulations where the ingredient story must link natural sourcing with waste reduction. Rousselot reported that its Peptan collagen peptide range received Upcycled Certified status in 2025, while its fish-derived range is positioned with Friend of the Sea certification ^{[3]nutritioninsight.com - https://www.nutritioninsight.com/news/fie-2024-rousselots-collagen-and-gelatin-advance-clean-label-and-functional-nutrition.html}. Nitta Gelatin has reported Aquaculture Stewardship Council certification for its freshwater fish collagen peptide ingredients. Such claims affect procurement because brand owners increasingly need evidence that an ingredient's sustainability narrative is supported by a defined sourcing and certification chain.

This driver is most commercially relevant in dietary supplements, functional food, and beauty-from-within products, where source transparency can influence both product positioning and retailer acceptance. It also rewards manufacturers that can maintain sensory quality through processing. Rousselot presented formulation work indicating that collagen peptides can remain suitable for UHT beverages, baking, and hot-drink applications, widening the addressable food-and-beverage format base.

Clinical support for skin, joint, and healthy-aging uses

Demand is increasingly linked to product-specific evidence rather than collagen as a broad lifestyle claim. A randomized, double-blind trial involving 72 women reported improvements in skin elasticity after supplementation with bioactive collagen peptides, with wrinkle-volume results also reported during the study period ^{[4]nutrafoods.eu - https://www.nutrafoods.eu/index.php/nutra/article/view/8}. A separate placebo-controlled study of fish-derived liquid collagen in photo-aged participants reported improvements in hydration, roughness, and elasticity measures. These findings support continued use in beauty-oriented supplements, but they do not eliminate the need for each supplier to establish the relevance of its own composition and dose.

Evidence-led joint-health positioning is also commercially important. A multicenter trial of specific collagen peptides in participants with functional knee and hip pain reported statistically significant reductions in pain outcomes after 12 weeks of supplementation. The implication for formulators is that clinical positioning can sustain premium pricing, but only when the ingredient identity, dosage, and study context are clearly connected to the product proposition.

Differentiation from mammalian collagen

Fish-derived inputs offer an alternative for manufacturers seeking to avoid bovine and porcine sources. Their differentiation is strongest where religious compatibility, marine sourcing, or byproduct valorization is relevant to the target market. Research comparing gelatin hydrolysates from different animal sources found distinct hydroxyproline-containing peptide profiles in blood after ingestion, including profiles associated with fish-scale hydrolysate. This gives suppliers a technical basis for emphasizing composition, although source origin alone should not be presented as proof of superior clinical outcomes.

The preference shift is also supported by circular-economy economics. Skins, bones, and scales are already generated within seafood processing, so collagen production can improve the value recovered per unit of fish processed. The commercial consequence is a stronger incentive for integrated processors to invest in extraction and fractionation capacity, especially where they can secure consistent species-specific feedstock.

Key Restraints

Inconsistent standardization of bioactive peptide compositions

Fish collagen peptides are not a single chemically uniform ingredient. Their molecular-weight profile, amino-acid sequence distribution, and functional properties vary by fish species, tissue source, extraction conditions, hydrolysis enzyme, and filtration protocol. This variability makes it difficult for a customer to substitute one supplier's peptide product for another without reassessing sensory properties, dosage, quality controls, and, in evidence-led products, claim substantiation.

The European Food Safety Authority's assessment of a collagen-hydrolysate joint-health claim illustrates the regulatory significance of composition-specific evidence; the proposed claim was not authorized under the relevant EU framework. The Gelatin Manufacturers of Europe updated its collagen peptide monograph in 2024 to address quality criteria for edible collagen peptides. Industry guidance can improve comparability, but it does not replace product-specific clinical and regulatory evidence where a health claim is sought.

Raw-material quality and yield variability

Feedstock availability does not ensure feedstock consistency. Collagen yield can vary by species, tissue condition, season, and processing history, while scales and bones require demineralization before extraction. Fish byproducts also require robust controls for freshness, traceability, and potential contaminants before they can enter premium human-nutrition supply chains.

The quality burden rises in ultra-low and narrowly defined molecular-weight products. A manufacturer must control hydrolysis variables and ultrafiltration performance tightly enough to reproduce the target fraction from batch to batch. This increases analytical, qualification, and operating costs, and it favors producers with integrated quality systems over suppliers competing solely on raw-material access.

The restraint profile also creates a useful separation between commodity and evidence-led demand. Standardization challenges slow broad health-claim expansion, particularly in tightly regulated markets, but they raise switching costs for suppliers whose compositions are already qualified. Meanwhile, raw-material variability creates an incentive for multi-feedstock processing and disciplined supplier controls. Animal nutrition, with a forecast 11.28% CAGR, offers a comparatively accessible scaling route, while pharmaceutical applications require more rigorous validation but provide a higher-value path for differentiated peptide systems.

Fish Collagen Peptides Market Segment Analysis

By Raw Material Source

Skin is the largest source category, valued at $467.5 million in 2025 and forecast to reach $931.0 million by 2035, at an approximately 7.13% CAGR. Its 55% market share reflects practical processing advantages: skins are collagen-rich, available in large volumes from filleting operations, and generally avoid the intensive demineralization step required for scales and bones. This makes skin the preferred feedstock for large-volume nutraceutical and cosmetic ingredients, particularly when the supplier needs a stable source for clinically positioned products.

Bones account for $170.0 million in 2025 and are projected to reach $367.5 million by 2035, expanding at an approximately 8.01% CAGR. Their value proposition is tied to fuller byproduct utilization and to potential applications in mineral-associated nutrition. Research on tuna-processing byproducts has examined gelatin peptides and peptide-calcium chelates derived from skins and bones, illustrating the opportunity to create more specialized bone-health ingredients rather than treating bone residues as lower-value material ^{[5]sciencedirect.com - https://www.sciencedirect.com/science/article/abs/pii/S0308814624037725}.

Scales represent $127.5 million in 2025 and are forecast to reach $250.25 million by 2035, at an approximately 6.98% CAGR. They require demineralization, which adds process complexity, but they offer a high-volume feedstock source and a differentiated fish-origin peptide profile. Research on silver carp scale collagen peptides has identified antioxidant and tyrosinase-inhibition activity in an experimental cosmetic context ^{[6]mdpi.com - https://www.mdpi.com/2304-8158/12/7/1552}. Titan Biotech markets Titagen as a fish-scale-derived collagen peptide, demonstrating that scale-based sourcing can be commercially viable when paired with controlled hydrolysis and product positioning.

Fins are projected to rise from $85.0 million in 2025 to $201.25 million in 2035, at an approximately 8.98% CAGR. The segment's growth reflects fuller utilization of fish-processing residues rather than a displacement of skin as the principal input. Producers able to process several source streams can reduce dependence on a single feedstock and improve plant utilization, although formulation-grade consistency remains the limiting operational requirement.

By Molecular Weight

Ultra-low molecular weight peptides below 1 kDa account for $127.5 million in 2025 and are expected to reach $253.75 million by 2035. Their commercial appeal lies in premium positioning around small peptide fractions and serving-size efficiency. PB Leiner has positioned Solugel Supra as a low-molecular-weight collagen ingredient with substantial di- and tripeptide content, showing how molecular characterization is becoming part of the commercial proposition.

Low molecular weight peptides from 1 to 3 kDa are the largest molecular-weight category at $340.0 million in 2025, representing 40% of market value. This is the market's established formulation range, balancing dispersibility, sensory performance, and broad applicability in powders, sachets, beverages, and beauty supplements. Its scale makes it the most exposed category to price competition, while branded evidence and reliable supply continue to determine who can defend margins.

Medium molecular weight peptides from 3 to 5 kDa are valued at $212.5 million in 2025 and forecast to reach $428.75 million by 2035. These fractions support applications where functionality and biological activity must be balanced with beverage compatibility and manageable viscosity. Marine fish proteins and peptides have been studied for mechanisms relevant to cosmetic applications, including matrix metalloproteinase-related activity, although laboratory findings should not be generalized to all commercial peptide products.

High molecular weight peptides from 5 to 10 kDa rise from $127.5 million in 2025 to $297.5 million in 2035, at an approximately 8.84% CAGR. Their growth is linked to food texture, specialized nutrition, wound-care, and biomedical-oriented use cases where the product is not defined solely by rapid absorption. Gelita's PEPTIPLUS platform illustrates the broader movement toward condition- and application-specific collagen peptide offerings.

Other specialty fractions account for $42.5 million in 2025 and are forecast to reach $117.25 million by 2035, the fastest growth rate among molecular-weight categories at approximately 10.58%. This category includes tripeptide-rich and non-standard fractions that can support targeted product positioning. Its expansion will depend less on the label "ultra-low" than on whether a producer can demonstrate stable composition, palatability, and relevance to a defined application.

By Application

Nutraceuticals remain the largest application, valued at $365.5 million in 2025 and projected to reach $721.0 million by 2035. Dietary supplements are the core demand base, while functional foods offer incremental volume through powders, beverage mixes, bars, gummies, and other convenient formats. The segment's commercial structure increasingly favors ingredients supported by sensory data, source documentation, and application-specific clinical evidence rather than generic collagen claims.

Cosmetics account for $255.0 million in 2025 and are projected to reach $495.25 million by 2035. Skincare and nutricosmetics are the primary demand pools, while haircare and injectables are more specialized. Oral beauty products benefit from the evidence base around skin hydration, elasticity, and wrinkle-related endpoints, whereas topical claims require more careful separation between ingredient functionality and finished-product performance. Injectable fish collagen remains a small, regulated niche where sterile manufacturing and validation requirements are significant barriers.

Food and beverage is forecast to grow from $170.0 million in 2025 to $376.25 million in 2035, at an approximately 8.27% CAGR. This growth depends on resolving taste, solubility, and heat-stability constraints that historically limited collagen use outside powders and capsules. Demonstrated compatibility with UHT, bakery, and hot-beverage conditions broadens use in ready-to-drink products, protein bars, soups, and fortified foods. Formulators that select low-odor, readily dispersible fractions can use mainstream grocery formats to move collagen consumption beyond specialist wellness channels.

Pharmaceuticals grow from $34.0 million in 2025 to $82.25 million in 2035, at an approximately 9.24% CAGR. The segment includes specialized clinical-nutrition, musculoskeletal, metabolic, wound-care, and tissue-support applications. Rousselot introduced Nextida GC in 2024 as a collagen peptide composition positioned around GLP-1 release and post-meal glucose control, demonstrating how suppliers are seeking defined metabolic-health applications beyond beauty and joint health. Regulatory substantiation and composition control will determine how much of this forecast becomes premium ingredient value rather than early-stage product experimentation.

Animal nutrition is the smallest application at $25.5 million in 2025 but the fastest growing, reaching $75.25 million by 2035 at an approximately 11.28% CAGR. Companion-animal joint health is an important premium opportunity, while livestock and aquaculture feed applications can provide volume. Collagen Lifesciences markets PETPEP for companion-animal applications, reflecting the transfer of human-health ingredient concepts into pet nutrition. The segment gives suppliers an additional outlet for collagen derivatives, although product quality and feed-regulatory requirements remain market-specific.

By Distribution Channel

Online retail/e-commerce is the largest channel, accounting for $297.5 million in 2025 and projected to reach $581.0 million in 2035. Digital channels support detailed explanations of source, dosage, certifications, and clinical positioning, which is particularly useful for an ingredient category that requires consumer education. They also enable subscription models and direct feedback loops, but they intensify price visibility and raise the cost of defending differentiation without recognizable evidence or brand assets.

Pharmacies and drug stores account for $212.5 million in 2025. The channel is important for health-oriented products because retail placement can lend credibility where consumers compare multiple collagen claims. It is especially relevant in markets where function-related product communication is regulated and a pharmacy setting helps signal quality and professional positioning.

Supermarkets and hypermarkets are forecast to grow from $170.0 million in 2025 to $367.5 million in 2035. Their approximately 8.01% CAGR reflects the shift from specialist supplement formats toward collagen-fortified food, beverage, and beauty products. Grocery expansion can increase volume materially, but it also requires price points, taste, shelf stability, and package communication that fit routine food purchasing rather than premium supplement behavior.

Specialty stores increase from $127.5 million to $283.5 million over the forecast period. Their approximately 8.32% CAGR reflects the advantage of curated health, sports-nutrition, and premium-beauty environments for explaining certification and composition differences. These outlets are valuable launch channels for higher-specification products before broader retail expansion.

Direct-to-consumer sales rise from $42.5 million in 2025 to $92.75 million in 2035. The channel remains smaller because many collagen peptide producers are ingredient suppliers rather than consumer brands. It is most effective for companies that own the final brand, have credible substantiation, and can sustain customer acquisition and repeat-purchase economics.

The fastest growth opportunities are concentrated in applications where the current category is underdeveloped: pharmaceuticals, animal nutrition, specialty molecular fractions, and food-and-beverage formats. These areas do not share one route to market. Pharmaceutical growth depends on validation and regulatory discipline; animal nutrition depends on product performance and feed-market access; food and beverage depends on sensory and processing compatibility. Suppliers that apply the same commodity powder strategy across all four areas will not capture their full value.

Fish Collagen Peptides Market Regional Analysis

Asia Pacific

Asia Pacific is the largest regional market, valued at $510.0 million in 2025 and forecast to reach $1,018.5 million by 2035, at an approximately 7.16% CAGR. Its 60% share combines seafood-processing capacity, established marine-ingredient supply networks, and a long-standing consumer association between collagen and beauty or healthy aging.

China is a major production and consumption center, supported by extensive seafood-processing infrastructure and a large domestic market for beauty supplements and functional foods. However, EU import controls affecting Chinese-origin collagen limit direct access to parts of the European market and increase the importance of compliant alternative sourcing routes ^{[7]food.ec.europa.eu - https://food.ec.europa.eu/animals/veterinary-border-control/faqs/faqs-human-consumption-hc\_en}. This creates an advantage for Chinese suppliers focused on domestic, regional, and non-EU export markets, while also creating room for Indian, Brazilian, and European producers in regulated import destinations.

Japan is the region's mature premium market. Consumer familiarity with collagen, sophisticated beauty and wellness positioning, and a regulatory environment that rewards substantiated function-related products support demand for higher-value formulations. Japan therefore remains an important reference market for brands that can pair marine sourcing with clear dosage, quality, and efficacy communication.

India is becoming more significant as a manufacturing and export base. Amar Aquatic, Athos Collagen, Collagen Lifesciences, and Titan Biotech illustrate the breadth of India's emerging supply base, ranging from ultra-low-molecular-weight scale collagen to large multi-source ingredient portfolios ^{[8]titagencollagen.com - https://www.titagencollagen.com}. The country's opportunity is not simply low-cost processing; it is the ability to meet the documentation, certification, and quality expectations of overseas customers.

South Korea combines an influential beauty market with advanced online retail and a strong preference for clinically positioned wellness products. Australia provides a smaller but attractive market supported by developed health-and-wellness retail and demand for traceable, sustainability-oriented marine ingredients.

North America

North America is valued at $212.5 million in 2025 and projected to reach $423.5 million by 2035, at an approximately 7.14% CAGR. The United States is the principal market, supported by a large supplement sector, mature direct-to-consumer infrastructure, and broad availability of specialty retail. The region rewards source certification and clinical credibility because premium consumers can readily compare ingredients, claims, and price points online.

The United States also benefits from an established regulatory environment for dietary ingredients and a broad health-and-wellness retail ecosystem. For fish collagen suppliers, fish allergen disclosure and substantiated product communication are essential operational requirements. Canada is a smaller but strategically useful extension market, particularly for brands with North American distribution and beauty-oriented collagen portfolios.

Europe

Europe is valued at $85.0 million in 2025 and forecast to reach $192.5 million by 2035, at an approximately 8.52% CAGR. The region's comparatively high growth rate reflects an expanding premium market built around traceability, sustainability, and disciplined health-claim communication. Regulatory complexity raises entry costs, but it also supports qualified suppliers by making compliance a meaningful procurement criterion.

Germany is the largest regional market, backed by established nutraceutical, functional-food, and specialty-retail infrastructure. The UK remains important for direct-to-consumer beauty supplements and premium health brands. France, Spain, and Italy offer growing demand through beauty, food, and wellness channels, although national commercialization requirements and distribution structures vary. European import rules make origin, approved-establishment status, and documentation central to supplier selection.

Latin America

Latin America is projected to expand from $25.5 million in 2025 to $73.5 million in 2035, at an approximately 11.17% CAGR. Brazil is the largest regional market and has relevance as both a consumer market and a collagen-processing location. Its role in international seafood and protein supply chains can support both domestic demand and export-oriented ingredient production.

Mexico is the second principal market, benefiting from rising supplement penetration, modern retail expansion, and proximity to North American product and ingredient flows. The region's growth potential is substantial, but commercial success depends on navigating registration, distributor capability, price sensitivity, and local consumer education rather than relying on a uniform regional launch strategy.

Middle East & Africa

The Middle East & Africa market rises from $17.0 million in 2025 to $42.0 million in 2035, at an approximately 9.30% CAGR. Saudi Arabia and the UAE are the leading Gulf opportunities, where premium health-and-wellness spending and halal-compatible marine sourcing support demand for fish collagen products. Here, the fish origin can be commercially meaningful because it reduces concerns associated with porcine-derived alternatives.

South Africa remains the region's most developed supplement-retail market and a potential distribution base for neighboring countries. Across MEA, growth will be shaped less by ingredient awareness alone than by import economics, certification recognition, e-commerce fulfillment, and the ability of distributors to build credible premium-health positioning.

India is positioned between these systems: it can serve domestic demand while building export capacity for customers seeking alternatives to restricted or less traceable supply routes. Latin America and MEA have smaller current values but higher projected growth rates, meaning that early work on registration, distributor selection, and channel design can matter more than immediate market size. The commercial risk is treating these regions as residual export outlets; their different regulatory, price, and retail conditions require distinct market-entry models.

Fish Collagen Peptides Market Share & Competitive Landscape

The market is moderately concentrated in premium branded ingredients and fragmented in regional commodity supply. Rousselot holds an approved 18.2% share of 2025 market value, Gelita AG holds 15.0%, Nitta Gelatin, Inc. holds 12.0%, Titan Biotech Limited holds 3.5%, and Collagen Lifesciences holds 2.5%. The remaining approximately 51.2% is distributed among regional suppliers, private-label producers, and specialty participants. Competitive advantage is increasingly determined by the combination of source certification, analytical capability, clinical support, application development, and regulatory documentation.

Rousselot holds the largest approved market share at 18.2%. Its Peptan platform covers multiple collagen sources, including fish-derived options, and its fish range is associated with Friend of the Sea and Upcycled Certified positioning. Rousselot's advantage lies in connecting branded ingredient identity with clinical research, applications support, and international scale. Its proposed combination with PB Leiner through the Nextida joint venture could further increase its manufacturing and geographic reach, subject to the transaction's completion ^{[9]investors.darlingii.com - https://investors.darlingii.com/news/news-details/2025/Darling-Ingredients-and-Tessenderlo-Group-Agree-to-Form-New-Company-to-Accelerate-Growth-in-Attractive-Collagen-Based-Health-Wellness-and-Nutrition-Sector/default.aspx}.

Nitta Gelatin, Inc. holds an approved 12.0% share. Through Wellnex, it positions fish collagen ingredients around dipeptide content, skin-health applications, and aquaculture-linked sourcing certification. Its ASC-certified fish collagen peptide program gives the company a distinct sustainability and traceability proposition for brands seeking freshwater aquaculture sourcing.

Gelita AG holds an approved 15.0% share and competes through a portfolio of application-specific bioactive collagen peptide brands, including VERISOL, PEPTIPLUS, FORTIBONE, and TENDOFORTE. The company's scale, long operating history, and global production footprint provide formulation and supply advantages, while its differentiated product platforms support condition-specific commercial positioning.

Athos Collagen Pvt Ltd is an India-based specialist fish-collagen producer that positions FiColla around ultra-low molecular weight, fish-scale sourcing, and a broad certification portfolio. Its dedicated fish-source manufacturing model is relevant to customers seeking non-mammalian supply and documentation for export-oriented formulations.

Titan Biotech Limited holds an approved 3.5% share. Through Titagen, it markets fish-scale collagen peptides for nutraceutical, cosmetic, food, and related applications. Its scale-derived product focus and international export orientation make it a notable participant in India's growing fish-collagen manufacturing base.

Atom Pharma is positioned as a supplier of pharmaceutical-grade hydrolyzed collagen within a broader pharmaceutical ingredients portfolio. Its competitive relevance is strongest in smaller-volume, specification-led applications rather than mass-market branded supplements. The company's role highlights the distinction between collagen sold as a general nutrition ingredient and material qualified for more controlled pharmaceutical and clinical-nutrition use.

Collagen Lifesciences holds an approved 2.5% share. Its portfolio includes AQUACOL and AQUAPRO fish collagen offerings, alongside multi-source collagen products. The company reports manufacturing capacity across three facilities and exports to more than 41 countries, giving it a broad B2B platform for international formulation customers.

Recent Industry Developments

May 2025 - Darling Ingredients and Tessenderlo Group announced a proposed Nextida joint venture.

The parties signed a non-binding term sheet to combine Rousselot and PB Leiner into a proposed collagen and gelatin business. Darling Ingredients stated that the entity would have approximately $1.5 billion in annual revenue and about 200,000 metric tons of capacity across 23 facilities, subject to definitive agreements and regulatory approvals.

April 2025 - Rousselot reported Upcycled Certified status for the Peptan range.

The certification recognizes the use of animal and fish byproducts that would otherwise be underutilized, reinforcing the brand's circular-sourcing position.